FGFR3 S249C is the most common activating FGFR3 mutation in urothelial carcinoma. Erdafit...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR3-S249C-UROTHELIAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-UROTHELIAL |
| Sources | SRC-CIVIC SRC-EAU-BLADDER-2024 SRC-NCCN-BLADDER-2025 |
Actionability Facts
| Biomarker | BIO-FGFR3-MUTATION |
|---|---|
| Variant | S249C |
| Disease | DIS-UROTHELIAL |
| ESCAT tier | IA |
| Recommended combinations | erdafitinib monotherapy |
| Evidence summary | FGFR3 S249C is the most common activating FGFR3 mutation in urothelial carcinoma. Erdafitinib is approved for FGFR3-altered metastatic urothelial carcinoma after platinum chemotherapy (THOR cohort 1, Loriot 2023 — OS benefit vs chemotherapy in 2L+). |
Notes
ESCAT IA per THOR cohort 1. OncoKB Level 1. Companion diagnostic: Therascreen FGFR RGQ RT-PCR Kit. Hyperphosphatemia and ocular toxicity (CSR) are erdafitinib class effects requiring monitoring.
Used By
No reverse references found in the YAML corpus.